Table 4.
Reported AR in multi-herb products from the scoping review categorized by System Organ Class (SOC), and the most frequently reported Preferred Terms (PTs).
| System Organ Class (SOC) | Times Reported (n=) | Percentage (%) * | Preferred Term (PT) | Times Reported (n=) | Percentage (%) * |
|---|---|---|---|---|---|
| Reproductive system and breast disorders | 60 | 29.7 | Vaginal bleeding/spotting | 28 | 13.9 |
| Thickened endometrium | 21 | 10.4 | |||
| Breast pain/tenderness | 8 | 4.0 | |||
| Gastrointestinal disorders | 59 | 29.2 | Diarrhea/loose stools | 17 | 8.4 |
| Gastrointestinal disorders (unspecified) | 10 | 5.0 | |||
| Nausea | 9 | 4.5 | |||
| Respiratory, thoracic, and mediastinal disorders | 19 | 9.4 | Respiratory, thoracic, and mediastinal disorders (unspecified) | 18 | 8.9 |
| Aggravation of asthma | 1 | 0.5 | |||
| Nervous system disorders | 16 | 7.9 | Nervous system disorders (unspecified) | 13 | 6.4 |
| Headache | 3 | 1.5 | |||
| Musculoskeletal and connective tissue disorders | 10 | 5.0 | Musculoskeletal and connective tissue disorders (unspecified) | 10 | 5.0 |
| General disorders | 8 | 4.0 | General disorders (unspecified) | 6 | 3.0 |
| Oedema | 1 | 0.5 | |||
| Influenza | 1 | 0.5 |
* Calculated as the percentage of the total AR reported during use of multi-herb products (n = 202).